Search results for "EWS"

showing 10 items of 1197 documents

In the literature: October 2020.

2020

Immune checkpoint inhibitors are widely used as treatment for an increasing number of solid tumours. Nevertheless, the lack of predictive biomarker represents a limitation across several cancer types. During the last years, the possibility to dynamically study tumour evolution through circulating tumour DNA (ctDNA) in plasma has opened novel possibility in evaluating disease status and therapeutic response, especially in localised disease to predict the possibility of relapse. However, the specific opportunities for application in the context of immunotherapy remain to be clarified.1 In an article recently published in Cancer Discovery by Zhang et al ,2 a comprehensive analysis of ctDNA dat…

OncologyCancer Researchmedicine.medical_specialtyPrognostic variableDurvalumabbusiness.industryCancerMicrosatellite instabilityContext (language use)DiseaseNewsmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282not applicableOncologyInternal medicinemedicine1506Lung cancerbusinessTremelimumabmedicine.drugESMO open
researchProduct

In the literature: October 2018

2018

Several trials with the check-point inhibitors pembrolizumab or nivolumab demonstrated some antitumour efficacy in chemorefractory advanced gastric cancer with a response rate ranging from 10% to 26%. However, no clear predictive biomarkers were found to facilitate a proper selection of patients. A series of 61 patients with advanced gastric cancer received second-line or third-line treatment with pembrolizumab in a prospective phase 2 trial.1 In a cooperative effort carried out by Korean and American investigators, a molecular characterisation of all tumours was performed including whole-exome sequencing and RNA sequencing of tissue biopsies, as well as circulating tumour DNA (ctDNA) from …

OncologyCancer Researchmedicine.medical_specialtybiologybusiness.industryliteratureMicrosatellite instabilityCancerPembrolizumabNewsmedicine.diseaseMLH1digestive system diseasesOncologyInternal medicinemedicinebiology.proteinImmunohistochemistryMicrosatellite1506AntibodyNivolumabbusinessESMO Open
researchProduct

In the literature: December 2018

2018

The current development of immune checkpoint modulatory treatments has shown durable responses in the treatment of multiple cancer types.1 However, predictive biomarkers beyond PD-1 ligand 1 (PD-L1) expression and high microsatellite instability (MSI-H) to stratify patients and identify those who could benefit of these therapies are needed. In this sense, a recent study published in Science by Cristescu et al 2 describes the potential usefulness of combining the tumour mutational burden (TMB) and the T cell-inflamed gene expression profile (GEP) to jointly predict clinical response to pembrolizumab. Both PD-L1 and the GEP represent a T cell-inflamed tumour microenvironment (TME), whereas TM…

OncologyCancer Researchmedicine.medical_specialtybusiness.industryMelanomaliteratureMicrosatellite instabilityPembrolizumabNewsmedicine.diseaseGermlineImmune checkpointGene expression profilingClinical trialOncologyInternal medicineGene expressionmedicine1506businessESMO Open
researchProduct

In the literature: June 2019

2019

Biliary tract cancer (BTC) includes cholangiocarcinoma and gallbladder cancer. BTCs are known to have a poor prognosis, with a 5-year overall survival below 20%.1 Unfortunately, majority of patients are diagnosed with advanced stage, being palliative chemotherapy with cisplatin and gemcitabine the current standard of care.2 Poor prognosis is due to the fact that only 20% of patients are diagnosed in early stages3 and the high risk of relapse following curative surgery. Unfortunately, the lack of randomised studies has made the role of adjuvant treatment in BTC following surgery an unresolved matter for many years.4 5 Adjuvant therapy (either in the form of chemotherapy or chemoradiotherapy)…

OncologyCancer Researchmedicine.medical_specialtybusiness.industryliteratureGemOxNewsmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282GemcitabineBile duct cancerOxaliplatinCapecitabineOncologyInternal medicinemedicineAdjuvant therapy1506Gallbladder cancerbusinessChemoradiotherapymedicine.drugESMO Open
researchProduct

Horizon Europe, the new programme for research & innovation: Which opportunities for GI research in the years to come?

2021

OncologyHorizon (archaeology)Economybusiness.industryHorizon EuropeGastroenterologyMedicineGI researchERCexcellent scienceMSCANewsbusiness
researchProduct

Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma

2020

Abstract Sorafenib and lenvatinib are approved for first‐line treatment of patients with advanced hepatocellular carcinoma (HCC), and the efficacy of atezolizumab plus bevacizumab has been demonstrated versus sorafenib. Over time, first‐line treatment frequently fails, and regorafenib, cabozantinib, ramucirumab (for patients with alpha fetoprotein ≥400 ng/mL), nivolumab, pembrolizumab and ipilimumab plus nivolumab are approved for use after sorafenib (but not lenvatinib) treatment in advanced HCC. Given the considerable complexity in the therapeutic landscape, the objective of this review was to summarize the clinical evidence for second‐line agents and provide practical guidance for select…

OncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularramucirumabReviewsAntineoplastic AgentsIpilimumabReviewPembrolizumabRamucirumab03 medical and health scienceschemistry.chemical_compound0302 clinical medicinecabozantinibAtezolizumabRegorafenibInternal medicinemedicineHumansipilimumabnivolumabHepatologybusiness.industryLiver Neoplasmshepatocellular carcinomaSorafenibdigestive system diseaseschemistry030220 oncology & carcinogenesisQuality of Liferegorafenib030211 gastroenterology & hepatologypembrolizumabNivolumabLenvatinibbusinessmedicine.drugLiver International
researchProduct

A Pooled Analysis of Extremely Low-Frequency Magnetic Fields and Childhood Brain Tumors

2010

Pooled analyses may provide etiologic insight about associations between exposure and disease. In contrast to childhood leukemia, no pooled analyses of childhood brain tumors and exposure to extremely low-frequency magnetic fields (ELF-MFs) have been conducted. The authors carried out a pooled analysis based on primary data (1960–2001) from 10 studies of ELF-MF exposure and childhood brain tumors to assess whether the combined results, adjusted for potential confounding, indicated an association. The odds ratios for childhood brain tumors in ELF-MF exposure categories of 0.1–<0.2 μT, 0.2–<0.4 μT, and ≥0.4 μT were 0.95 (95% confidence interval: 0.65, 1.41), 0.70 (95% CI: 0.40, 1.22), and 1.1…

Oncologymedicine.medical_specialtyNeoplasms Radiation-InducedChildhood leukemiaEpidemiologyBrain tumorGlobal HealthCentral nervous system diseaseElectromagnetic FieldsRisk FactorsInternal medicineEpidemiologymedicineHumansChildBrain Neoplasmsbusiness.industryIncidenceConfoundingOdds ratiomedicine.diseaseConfidence intervalSurgeryMeta-analysisbusinessSystematic Reviews and Meta- and Pooled AnalysesAmerican Journal of Epidemiology
researchProduct

Investigator-initiated trials of targeted oncology agents: why independent research is at risk?

2010

Background: Drug development traditionally has relied upon the complementary contributions of clinicians and scientists at academic institutions and at pharmaceutical companies. Greater regulatory burdens, increased bureaucratic requirements, restricted reimbursement, and spiralling research and development costs are exerting pressure on the drug development pipeline. The result is a de-emphasis of exploratory research, particularly independent academic research, despite its proven value in identifying new drug targets and developing innovative cancer therapies. Design: An expert panel assembled by the Biotherapy Development Association-a nonprofit international forum for academic and indus…

Oncologymedicine.medical_specialtyacademic research Clinical Trials Directive drug development investigator-initiated trials oncologytargeted therapiesSettore MED/06 - Oncologia MedicaeducationExploratory researchReviewsAntineoplastic AgentsPatient advocacyInternal medicineNeoplasmsmedicineHumanshealth care economics and organizationsReimbursementLicensureGovernmentClinical Trials as Topicbusiness.industryLegislatureHematologyResearch PersonnelClinical trialOncologyDrug developmentbusinessAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Navigating high-choice European political information environments : a comparative analysis of news user profiles and political knowledge

2021

The transition from low- to high-choice media environments has had far-reaching implications for citizens’ media use and its relationship with political knowledge. However, there is still a lack of comparative research on how citizens combine the usage of different media and how that is related to political knowledge. To fill this void, we use a unique cross-national survey about the online and offline media use habits of more than 28,000 individuals in 17 European countries. Our aim is to (i) profile different types of news consumers and (ii) understand how each user profile is linked to political knowledge acquisition. Our results show that five user profiles – news minimalists, social m…

Online and offlinecrossSociology and Political Sciencenews repertoires050801 communication & media studiescross-nationalnews media usePoliticsSeekers0508 media and communications10240 Department of Communication and Media Research3312 Sociology and Political ScienceComparative researchMedia usePolitical science050602 political science & public administrationcomparative researchSocial media070 News media journalism & publishingpolitical knowledgeUser profileCommunication05 social sciencesPoliticsnationalAdvertisingKnowledge acquisition[SHS.SCIPO]Humanities and Social Sciences/Political science0506 political scienceddc:Mass communications3315 CommunicationThe international journal of press/politics
researchProduct

Reframing Gender Equality in Finnish Online Discussion on Immigration: Populist Articulations of Religious Minorities and Marginalized Sexualities

2014

Gender equality is an essential part of Finnish self-understanding. The public discussion on equality does not, however, only focus on gender; it is also used to promote antiimmigration-minded, homophobic opinions. In the article, the co-existence of contradictory discourses on gender equality is interpreted as populist rhetoric. The articulations of gender equality in online debates on gender, sexuality, and immigration are analyzed. The main questions are: How is gender equality re-framed in anti-immigration-minded online debate? How are the notions of sexuality and gender fixed in order to oppose immigration? How are gender, sexuality, and immigration articulated intersectionally? The in…

Online discussionGender equalitymedia_common.quotation_subjectImmigrationHuman sexualityGender studiesCognitive reframingsukupuoliNewspaperGender StudiesmaahanmuuttoRhetoricuskonnolliset vähemmistötta616Sociologyequalitymarginalized sexualitiesArticulation (sociology)media_commonNORA - Nordic Journal of Feminist and Gender Research
researchProduct